After the USPTO issued a final written decision that Mylan (MYL) has not shown that the Tecfidera '514 patent is unpatentable, Guggenheim analyst Yatin Suneja estimated that five years of additional Tecfidera exclusivity could be worth $80-$90 per Biogen (BIIB) share. The analyst, who called this decision the key near-term overhang on Biogen's stock, said that now "all eyes will be focused on adacanumab's BLA acceptance" and an FDA decision potentially later this year. Suneja has a Buy rating on Biogen shares, which have jumped $52.80, or 18.6%, to $336.09 in afternoon trading.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here